volanesorsen sodium: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
volanesorsen sodium: clinical details
Prescribing considerations
- Treatment should be supervised by a clinician experienced in FCS.
- Confirm FCS genetically, high pancreatitis risk and inadequate response to dietary and triglyceride-lowering measures.
- Exclude secondary causes of severe hypertriglyceridaemia before treatment.
- People with lower body weight may be more susceptible to thrombocytopenia.
- Safety and efficacy have not been established below 18 years; evidence in older adults is limited.
- Severe renal impairment and hepatic impairment have not been adequately studied.
Contraindications and cautions
- Hypersensitivity to volanesorsen or an excipient.
- Chronic or unexplained thrombocytopenia.
- Do not initiate when the platelet count is below the product-specific threshold.
Monitoring
- Platelet count before treatment and regularly thereafter, with prompt assessment of bleeding symptoms.
- Triglycerides to assess response.
- Urinalysis and renal function for nephrotoxicity.
- Liver enzymes and bilirubin for hepatotoxicity.
- Inflammatory markers as described in the product information.
- LDL cholesterol, which may increase during treatment.
Clinical pharmacology
Volanesorsen is a highly protein-bound antisense oligonucleotide targeting apoC-III mRNA. It is distributed rapidly into tissues, metabolised by endonucleases and exonucleases rather than cytochrome P450 enzymes, and eliminated slowly through tissue metabolism and urinary excretion.
Formulation and product differences
- The selected product is a clear, colourless to slightly yellow solution in a single-use pre-filled syringe for subcutaneous administration.
- It must not be mixed with other medicinal products and should be protected from freezing and light.
volanesorsen sodium interactions
Formal clinical interaction studies have not been conducted. The prescribing team should review all medicines, including non-prescription products.
Anticoagulants and antiplatelet medicines, including warfarin, aspirin, clopidogrel, ticagrelor, prasugrel and dipyridamole
These affect clotting and may compound bleeding concerns if volanesorsen lowers platelet counts.
Non-steroidal anti-inflammatory drugs, including ibuprofen
These can impair platelet function, so use should be reviewed in the context of platelet results and bleeding risk.
Medicines that may reduce platelet counts, including quinine and some antibiotics
Combined use may increase concern about thrombocytopenia and requires specialist review.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.